Panel Chairman
Professor Simon Kroll
MA BM BCh FRCPCH FRCP FMedSci
Professor Kroll is Professor of Paediatrics and Molecular Infectious Diseases at Imperial College and St. Mary's Hospital, London. He is involved in Research into the molecular basis of the virulence of meningitis pathogens, and new vaccine strategies to prevent meningitis and septicaemia. |  |
Other Members
Dr Ray Borrow Ph.D.
Head of Vaccine Evaluation Department, Manchester Medical Microbiology Partnership, Manchester
Dr. Helen Bedford BSc, MSc, PhD, RGN, RHV, MFPHM, MRCPCH
Lecturer in the Epidemiology of Child Health
Paediatric Epidemiology & Biostatics, Institute of Child Health, London
Dr. Philip Monk OBE, FFPHM MRCGP
Consultant in Health Protection, Leicestershire, Northamptonshire & Rutland Strategic Health Authority, Leicester
Dr. Alistair Thomson MA, MD, BChir, FRCPCH, FRCP, DCH, DRCOG
Consultant Paediatrician, Mid-Cheshire Hospitals NHS Trust, Leighton Hospital, Crewe
Dr. James Stuart MA, MB, BChir, FFPH
Regional Director, Health Protection Agency, South West
Medical Director
|
Professor Keith Cartwright
MA BM FRCPath FFPH
Professor Cartwright is the Meningitis Trust's medical director and as such acts as an ex-officio member of the research advisory panel. He was Director of the Public
Health Laboratory at Gloucester from 1981 to 1995 and then Group Director of PHLS South West until the closure of the
PHLS in 2003. His final post before retirement in July 2004 was as Head of Intervention Policy and R&D for the
newly created Health Protection Agency.
His principal research interests have been in the epidemiology, diagnosis and management of meningococcal disease and other severe community-acquired infections. He retired
from the UK Department of Health's Joint Committee on Vaccination and Immunisation in 2006 but continues as a member of the HPA Meningococcus Forum and Pneumococcus and Hib Forum.
He now carries out a substantial amount of medico-legal work, mainly in the field of meningitis and other central nervous system infections. He also continues to undertake
clinical trials of new vaccines.
|
|
<< Back to Research Page
